Synairgen (LON:SNG) Trading Down 0.2% – Should You Sell?

Synairgen plc (LON:SNG) shares dropped 0.2% on Monday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02). Approximately 478,281 shares were traded during trading, a decline of 82% from the average daily volume of 2,614,922 shares. The stock had previously closed at GBX 2 ($0.02).

Synairgen Price Performance

The stock has a market capitalization of £3.69 million, a P/E ratio of -61.00 and a beta of -2.23. The business’s 50 day simple moving average is GBX 3.51 and its two-hundred day simple moving average is GBX 3.91. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).